ERBB2 and gastric cancer: The molecular and immune microenvironment characteristics of HER2‐positive gastric cancer related to favorable response to first‐line trastuzumab‐based treatment were cell cycle‐related gene alterations including CCNE1 amplification, increased CD3‐CD57+ NK cell infiltration, and increased PD‐L1 combined positive score.